Problematic of doping in general practice

Česká verzia

Authors: D. Pastucha ¹; E. Sovová ¹; R. Tichá ¹; V. Talafa ²; R. Filipčíková ³; M. Bezdičková ³; Z. Blažková ³
Authors place of work: Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace FN a LF UP, Olomouc Přednosta: doc. MUDr. Eliška Sovová, PhD., MBA ¹; Interní oddělení Nemocnice s poliklinikou Frýdek Místek Primář: MUDr. Petr Vítek ²; Ústav normální anatomie LF UP, Olomouc Přednosta: doc. MUDr. Stanislav Laichman, CSc. ³
Published in the journal: Prakt. Lék. 2011; 91(8): 448-452
Category: Reviews

Summary

The issue of doping is becoming an increasingly common aspect of patient care at first contact, i.e. at the general practitioners. The aim of this article is to provide general practitioners with a general introduction to the issue of doping, drawing attention to the biochemical and physiological aspects, and possible adverse effects, of such prohibited substances; and further to warn against possible damage to the patient (top athletes) through incorrect prescription of any prohibited substance.

Key words:
doping; anabolic steroid; general practitioner.

Zdroje

1. Jeschke, J., Nekola, J., Chlumský, J. Doping ve sportu. Čas. Lék. čes., 1999, s. 291-297.

2. WADA. The Code. (cit. 2011-06-26). Dostupný na WWW: <http://wada-ama.org>

3. Antidopingový výbor ČR. Seznam zakázaných látek a metod 2011. (cit. 2011-06-26). Dostupný na WWW: <http:// antidoping.cz/seznam_zakazanych_metod_2011.php >

4. WADA. The prohibited list. (cit. 2011-06-26). Dostupný na WWW: <http://wada-ama.org>

5. Antidopingový výbor ČR. Seznam zakázaných látek a metod 2011. (cit. 2011-06-26). Dostupný na WWW: <http:// antidoping.cz/seznam_zakazanych_metod_2011.php >

6. Lippi, G., Franchini, M., Banfi, G. Biochemistry and physiology of anabolic androgenic steroids doping. Mini Rev. Med. Chem. 2011, 11(5), p. 362-373.

7. Holt, R.I., Erotokritou-Mulligan, I., Sönksen, P.H. The history of doping and growth hormone abuse in sport. Growth Horm IGF Res, 2009, 19(4), p. 320-326.

8. Thevis, M., Sigmund, G., Geyer, H., Schänzer, W. Stimulants and doping in sport. Endocrinol. Metab. Clin. North Am. 2010, 39(l1), p. 89-105.

9. Martino, M., Gledhill, N., Jamnik, V. High VO2max with no history of training is primarily due to high blood volume. Med. Sci. Sports. Exerc. 2002, 34(6), p. 966-971.

10. Schmidt, W., Prommer, N. Impact of alterations in total hemoglobin mass on VO2max. Exerc. Sport Sci. Rev. 2010, 38(2), p. 68-75.

11. Jelkmann, W., Lundby, C. Blood doping and its detection. Blood 2011, 7. In press.

12. Rankinen, T., Perusse, L., Rauramaa, R. et al. The human gene map for performance and health-related fitness phenotypes. Med. Sci. Sports Exerc. 2006, 33, p. 1219-1233.

13. Fineschi, V. Anabolic androgenic steroids (AAS) as doping agents: chemical structures, metabolism, cellular responses, physiological and pathological effects. Mini Rev. Med. Chem. 2011, 11(5), p. 359-361.

14. Hassan, N.A., Salem, M.F., Sayed, M.A. Doping and effects of anabolic androgenic steroids on the heart: histological, ultrastructural, and echocardiographic assessment in strength athletes. Hum. Exp. Toxicol. 2009, 28(5), p. 273-283.

15. Hartgens, F., Kuipers, H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004, 34(8), p. 513-554.

16. Boyadjiev, N.P., Georgieva, K.N., Massaldjieva, R.I., Gueorguiev, S.I. Reversible hypogonadism and azoospermia as a result of anabolic-androgenic steroid use in a body builder with personality disorder. J. Sports Med. Phys. Fitness. 2000; 40(3), p. 271-274.

17. Pastucha, D., Malinčíková, J., Tichá, R. Rizika sportovní aktivity v dětském věku. Pediatr. pro Praxi, 2010, 11(4), s. 224-227.